Horizon Therapeutics Publ... (HZNP)
Horizon Therapeutics Public Statistics
Share Statistics
Horizon Therapeutics Public has 228.74M shares outstanding. The number of shares has increased by -0.39% in one year.
| Shares Outstanding | 228.74M |
| Shares Change (YoY) | -0.39% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 211.06M |
| Failed to Deliver (FTD) Shares | 490 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 50 and the forward PE ratio is null. Horizon Therapeutics Public's PEG ratio is -13.17.
| PE Ratio | 50 |
| Forward PE | n/a |
| PS Ratio | 7.18 |
| Forward PS | 5.6 |
| PB Ratio | 5.14 |
| P/FCF Ratio | 23.04 |
| PEG Ratio | -13.17 |
Enterprise Valuation
Horizon Therapeutics Public has an Enterprise Value (EV) of 26.28B.
| EV / Sales | 7.24 |
| EV / EBITDA | 23.58 |
| EV / EBIT | 20.89 |
| EV / FCF | 23.23 |
Financial Position
The company has a current ratio of 3.85, with a Debt / Equity ratio of 0.51.
| Current Ratio | 3.85 |
| Quick Ratio | 3.67 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | 2.3 |
| Debt / FCF | 2.26 |
| Interest Coverage | 7.38 |
Financial Efficiency
Return on Equity is 10.28% and Return on Invested Capital is 7.47%.
| Return on Equity | 10.28% |
| Return on Assets | 5.72% |
| Return on Invested Capital | 7.47% |
| Revenue Per Employee | $1.66M |
| Profits Per Employee | $238.12K |
| Employee Count | 2,190 |
| Asset Turnover | 0.4 |
| Inventory Turnover | 5.43 |
Taxes
| Income Tax | 5.45M |
| Effective Tax Rate | 1.04% |
Stock Price Statistics
The stock price has increased by 0% in the last 52 weeks. The beta is 1.01, so Horizon Therapeutics Public's price volatility has been higher than the market average.
| Beta | 1.01 |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 111.11 |
| 200-Day Moving Average | 108.3 |
| Relative Strength Index (RSI) | 83.96 |
| Average Volume (20 Days) | 23.92M |
Income Statement
In the last 12 months, Horizon Therapeutics Public had revenue of 3.63B and earned 521.48M in profits. Earnings per share was 2.28.
| Revenue | 3.63B |
| Gross Profit | 2.71B |
| Operating Income | 617.41M |
| Net Income | 521.48M |
| EBITDA | 1.11B |
| EBIT | 610.64M |
| Earnings Per Share (EPS) | 2.28 |
Balance Sheet
The company has 2.35B in cash and 2.56B in debt, giving a net cash position of -210M.
| Cash & Cash Equivalents | 2.35B |
| Total Debt | 2.56B |
| Net Cash | -210M |
| Retained Earnings | 590.01M |
| Total Assets | 9.3B |
| Working Capital | 3B |
Cash Flow
In the last 12 months, operating cash flow was 1.26B and capital expenditures -126.28M, giving a free cash flow of 1.13B.
| Operating Cash Flow | 1.26B |
| Capital Expenditures | -126.28M |
| Free Cash Flow | 1.13B |
| FCF Per Share | 4.94 |
Margins
Gross margin is 74.64%, with operating and profit margins of 17.01% and 14.37%.
| Gross Margin | 74.64% |
| Operating Margin | 17.01% |
| Pretax Margin | 14.52% |
| Profit Margin | 14.37% |
| EBITDA Margin | 30.71% |
| EBIT Margin | 17.01% |
| FCF Margin | 31.18% |
Dividends & Yields
HZNP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 2% |
| FCF Yield | 4.34% |
Analyst Forecast
Currently there are no analyst rating for HZNP.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 5.08 |
| Piotroski F-Score | 8 |